PT  - JOURNAL ARTICLE
AU  - Theresa Maier
AU  - Paula Peirce
AU  - Laura Baird
AU  - Sophie L. Whitehouse
AU  - Nigel K. H. Slater
AU  - Kathryn Beardsall
TI  - Therapeutic delivery from a solid formulation during breastfeeding: a feasibility study
AID  - 10.1101/2020.03.05.20031583
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.05.20031583
4099  - http://medrxiv.org/content/early/2020/03/10/2020.03.05.20031583.short
4100  - http://medrxiv.org/content/early/2020/03/10/2020.03.05.20031583.full
AB  - Background Enteral drug and nutrient delivery to breastfed infants depends on the use of oral syringes and liquid formulations. This can pose both practical and emotional challenges to drug delivery.Objectives The presented study aimed to explore the potential of using solid formulations for therapeutic delivery during breastfeeding.Methods Single centre feasibility study within a tertiary level neonatal unit in the UK, involving twenty-six breastfeeding mother-infant dyads. Vitamin B12 was delivered to infants during breastfeeding from a solid formulation within a commercial silicon nipple shield. Outcomes included the quantitative measurement of change in serum vitamin B12 and a mixed methods assessment of maternal expectations and experiences.Results Participants described the surprising ease of ‘drug’ delivery, with no negative impact on breastfeeding behaviour or sensation reported. Vitamin B12 levels rose on average from a baseline of 533 pg/mL (236 - 925 pg/mL) to 1871 pg/mL (610 – 4981 pg/mL) at 6 - 8 hours post-delivery. All mothers expressed their support for this approach, 85% a preference over the use of oral syringes. Reasoning for support related to the reduced medicalisation of this procedure compared to the use of oral syringes, and a desire for choices in relation to their infants’ health.Conclusions This study demonstrated that therapeutic delivery from a solid formulation within a nipple shield was feasible and acceptable to mothers and infants.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03799367Funding StatementThe research was supported by a University of Cambridge WD Armstrong PhD studentship, the University of Cambridge Kurt Hahn Trust, and the German Academic Scholarship Foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary material.